Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3
Quality Standards All medications are sourced from a licensed 503B pharmacy that follows strict safety, purity, and testing requirements
For additional background across GLP-1 choices and related therapies, see Type 2 Diabetes for educational articles and Diabetes Products to understand categories and device types
In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'" "Novo Nordisk is firm on our position and protecting patients living with obesity
However, the discomfort it causes might make it harder for you to eat the healthy, protein-rich foods your body needs, which could indirectly slow your progress